LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) Director Robert Bessler sold 894,337 shares of the business's stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares in the company, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Robert Bessler also recently made the following trade(s):
- On Tuesday, May 12th, Robert Bessler sold 575,034 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.02, for a total transaction of $4,611,772.68.
- On Thursday, May 7th, Robert Bessler sold 75,000 shares of LifeStance Health Group stock. The stock was sold at an average price of $8.55, for a total transaction of $641,250.00.
- On Friday, April 24th, Robert Bessler sold 62,147 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.05, for a total value of $438,136.35.
- On Thursday, April 23rd, Robert Bessler sold 7,752 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $54,264.00.
- On Tuesday, April 21st, Robert Bessler sold 5,101 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.01, for a total value of $35,758.01.
LifeStance Health Group Stock Up 3.9%
NASDAQ:LFST opened at $10.74 on Wednesday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The stock has a 50-day moving average price of $8.06 and a two-hundred day moving average price of $7.31. LifeStance Health Group, Inc. has a 1 year low of $3.74 and a 1 year high of $10.89. The stock has a market cap of $4.17 billion, a price-to-earnings ratio of 179.07 and a beta of 1.19.
LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.03. The business had revenue of $403.48 million for the quarter, compared to analyst estimates of $387.46 million. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The business's quarterly revenue was up 21.2% on a year-over-year basis. As a group, equities analysts expect that LifeStance Health Group, Inc. will post 0.12 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms have recently issued reports on LFST. Jefferies Financial Group upgraded shares of LifeStance Health Group to a "strong-buy" rating in a research note on Thursday, March 12th. Zacks Research upgraded LifeStance Health Group from a "hold" rating to a "strong-buy" rating in a research note on Monday, April 27th. The Goldman Sachs Group initiated coverage on LifeStance Health Group in a report on Friday, June 5th. They issued a "neutral" rating and a $9.00 price objective on the stock. Barclays lifted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock an "overweight" rating in a report on Friday, March 6th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of LifeStance Health Group in a research note on Wednesday, May 27th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.75.
Check Out Our Latest Research Report on LifeStance Health Group
Institutional Trading of LifeStance Health Group
Large investors have recently bought and sold shares of the business. Larson Financial Group LLC grew its position in shares of LifeStance Health Group by 19,952.6% during the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company's stock worth $27,000 after buying an additional 3,791 shares during the period. KBC Group NV acquired a new position in shares of LifeStance Health Group during the 1st quarter valued at $29,000. EverSource Wealth Advisors LLC boosted its stake in LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock worth $44,000 after acquiring an additional 5,404 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in LifeStance Health Group by 615.3% during the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock worth $59,000 after acquiring an additional 7,987 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in LifeStance Health Group by 17.0% in the first quarter. Assetmark Inc. now owns 9,419 shares of the company's stock worth $60,000 after purchasing an additional 1,367 shares during the period. 85.50% of the stock is currently owned by institutional investors and hedge funds.
About LifeStance Health Group
(
Get Free Report)
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
